Kadimastem Ltd (KMSTF)
USD 0.64
(-90.0%)
USD 0.64
(-90.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -630.13 Thousand USD | -14.36% |
| 2022 | -551 Thousand USD | 7.25% |
| 2021 | -594.07 Thousand USD | -4.86% |
| 2020 | -566.52 Thousand USD | -82.03% |
| 2019 | -311.23 Thousand USD | -168.59% |
| 2018 | -115.87 Thousand ILS | -1336.78% |
| 2017 | -8065.00 ILS | -103.82% |
| 2016 | 211.24 Thousand ILS | -77.09% |
| 2015 | 922 Thousand ILS | 264.43% |
| 2014 | 253 Thousand ILS | 80.71% |
| 2013 | 140 Thousand ILS | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | -311.2 Thousand USD | 0.0% |
| 2023 Q4 | -311.76 Thousand USD | 0.0% |
| 2023 FY | -630.13 Thousand USD | -14.36% |
| 2022 FY | -551 Thousand USD | 7.25% |
| 2022 Q2 | -267.7 Thousand USD | 0.0% |
| 2022 Q4 | -285.3 Thousand USD | 0.0% |
| 2021 Q2 | -278.65 Thousand USD | 0.0% |
| 2021 FY | -594.07 Thousand USD | -4.86% |
| 2021 Q4 | -301.86 Thousand USD | 0.0% |
| 2020 Q2 | -270.73 Thousand ILS | 0.0% |
| 2020 Q1 | - ILS | 100.0% |
| 2020 Q4 | -274.69 Thousand USD | 0.0% |
| 2020 FY | -566.52 Thousand USD | -82.03% |
| 2019 FY | -311.23 Thousand USD | -168.59% |
| 2019 Q4 | -219.74 Thousand USD | 0.0% |
| 2019 Q2 | -88.6 Thousand USD | 0.0% |
| 2018 FY | -115.87 Thousand ILS | -1336.78% |
| 2017 FY | -8065.00 ILS | -103.82% |
| 2016 FY | 211.24 Thousand ILS | -77.09% |
| 2015 FY | 922 Thousand ILS | 264.43% |
| 2014 FY | 253 Thousand ILS | 80.71% |
| 2013 FY | 140 Thousand ILS | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -25735.916% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 105.383% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -97.222% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.529% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 97.557% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -1205.742% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -407.149% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 104.201% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 20413.926% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 106.434% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 1058.706% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -1745.206% |
| Mesoblast Limited | -35.16 Million USD | 98.208% |
| Marizyme, Inc. | 457.7 Thousand USD | 237.674% |
| Genus plc | 178.7 Million USD | 100.353% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.286% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 1112.66% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 253.63% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -5628.527% |
| ContraFect Corporation | -154 Thousand USD | -309.181% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -1160.276% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 920.909% |
| IMV Inc. | -962.29 Thousand USD | 34.517% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -62.616% |
| MultiCell Technologies, Inc. | 49.32 USD | 1277752.068% |
| ONE Bio Corp. | 20.12 Million USD | 103.131% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 101.565% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 1388.626% |
| Q BioMed Inc. | -8988.00 USD | -6910.881% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 102.23% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -3985.438% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 101.421% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 44.801% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 1000.197% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -12624.919% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 548.497% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -546.196% |
| GB Sciences, Inc. | -624.00 USD | -100883.654% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -632.48% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.008% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -302850.962% |
| Enzolytics Inc. | 30.7 Thousand USD | 2152.032% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 230.617% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.057% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -22.473% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 202.066% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.154% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -7015.379% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -651.515% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 163.78% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 106.556% |
| BioStem Technologies, Inc. | 15.42 Million USD | 104.085% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -5224.36% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 456.897% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 456.897% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 146.431% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -2072.89% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 240.017% |
| SYBLEU INC | 11.69 Thousand USD | 5487.637% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 113.675% |
| Bioxytran, Inc. | -8285.00 USD | -7505.769% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -68.938% |
| Neutra Corp. | 14.33 Thousand USD | 4495.8% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -668.461% |
| PureTech Health plc | -1.6 Million USD | 60.69% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 37.064% |
| IXICO plc | 3.27 Million USD | 119.27% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 9.202% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 64.816% |
| CSL Limited | 7.7 Billion USD | 100.008% |
| Cellectis S.A. | 18 Thousand USD | 3600.767% |